CervoMed (NASDAQ:CRVO) Given “Buy” Rating at HC Wainwright

CervoMed (NASDAQ:CRVO)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a report released on Wednesday,Benzinga reports. HC Wainwright also issued estimates for CervoMed’s Q4 2026 earnings at ($0.59) EPS, FY2026 earnings at ($2.70) EPS, Q1 2027 earnings at ($0.51) EPS, Q2 2027 earnings at ($0.46) EPS, Q3 2027 earnings at ($0.50) EPS, Q4 2027 earnings at ($0.53) EPS and FY2027 earnings at ($1.99) EPS.

CRVO has been the topic of a number of other reports. D. Boral Capital reiterated a “buy” rating and set a $31.00 target price on shares of CervoMed in a research report on Wednesday, April 22nd. Roth Capital set a $9.00 price target on shares of CervoMed in a report on Monday, May 18th. Chardan Capital boosted their price objective on shares of CervoMed from $15.00 to $21.00 and gave the stock a “buy” rating in a research report on Wednesday, March 18th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CervoMed in a report on Monday, April 20th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $22.60.

CervoMed Price Performance

NASDAQ CRVO opened at $3.08 on Wednesday. The firm has a market cap of $41.67 million, a PE ratio of -0.94 and a beta of -0.68. CervoMed has a one year low of $2.13 and a one year high of $13.13. The stock’s 50 day simple moving average is $3.34 and its 200 day simple moving average is $4.48.

CervoMed (NASDAQ:CRVO) last posted its quarterly earnings data on Friday, May 15th. The company reported ($0.86) EPS for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.04. CervoMed had a negative return on equity of 136.08% and a negative net margin of 672.80%. As a group, equities analysts expect that CervoMed will post -2.84 earnings per share for the current year.

Insider Activity at CervoMed

In other CervoMed news, Director Joshua S. Boger purchased 955,414 shares of the company’s stock in a transaction that occurred on Thursday, June 11th. The stock was acquired at an average cost of $3.14 per share, with a total value of $2,999,999.96. Following the completion of the purchase, the director directly owned 1,795,865 shares in the company, valued at approximately $5,639,016.10. This represents a 113.68% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 35.80% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On CervoMed

A number of hedge funds and other institutional investors have recently bought and sold shares of CRVO. AQR Capital Management LLC acquired a new stake in CervoMed during the 1st quarter worth $227,000. Rhumbline Advisers grew its stake in shares of CervoMed by 35.5% during the first quarter. Rhumbline Advisers now owns 5,830 shares of the company’s stock worth $53,000 after purchasing an additional 1,526 shares during the period. Marshall Wace LLP bought a new stake in CervoMed in the second quarter valued at about $76,000. Jane Street Group LLC acquired a new position in CervoMed in the second quarter valued at about $414,000. Finally, Vanguard Group Inc. lifted its stake in CervoMed by 1.0% in the third quarter. Vanguard Group Inc. now owns 343,463 shares of the company’s stock valued at $2,779,000 after buying an additional 3,445 shares during the period. 25.15% of the stock is owned by institutional investors.

CervoMed Company Profile

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc was founded in 2010 and is headquartered in Boston, Massachusetts.